Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 15, 2009 Robert Steyer	Medicis Tries to Save Face The wrinkle-removal drugmaker hopes it can smooth out a tough economy.
The Motley Fool December 15, 2003 Alyce Lomax	No Wrinkles for Medicis Medicis Pharmaceuticals announced that the FDA has approved its injectable wrinkle-filling gel, Restylane. Allergan's Botox has found a new competitor in the fountain-of-youth market.
The Motley Fool May 27, 2009 Brian Orelli	A Wrinkle in the Botox Plan The FDA turns down Allergan's label expansion, but it wasn't all bad news.
The Motley Fool September 12, 2008 Brian Lawler	A New Wrinkle for an Old Drug Allergan's muscle relaxant Botox performs well in two studies testing its ability to prevent migraine headaches.
The Motley Fool January 2, 2004 Dave Marino-Nachison	Medicis: Skin Is In The drug maker has a strong balance sheet and a commitment to product development.
The Motley Fool June 29, 2009 Brian Orelli	REMS: Not Just for Sleeping Anymore Risk Evaluation and Mitigation Strategies is saving drugmakers from going into a deep sleep while they wait for Food and Drug Administration approval of their drugs.
The Motley Fool December 16, 2005 Stephen D. Simpson	A Romantic Rectangle in Health Care First Medicis wants Inamed, then Allergan wants Inamed. Now Mentor wants Medicis. Strange days in health care, to be sure. Investors, take note.
The Motley Fool August 8, 2006 Stephen D. Simpson	Waiting on Fine Figures From Mentor Flush with cash, medical aesthetics specialist Mentor needs to reinvest in growth. This is a fine company that rarely trades cheap -- investors, take note.
The Motley Fool November 17, 2008 Brian Orelli	Beauty Can Be a Beast Pinched pocketbooks are likely to hurt cosmetic-pharmaceutical companies more than any FDA warning.
The Motley Fool June 5, 2008 Brian Lawler	Allergan Lashes Out The pharmaceutical announces a new drug that could promote eyelash growth.
Chemistry World June 10, 2008 James Mitchell Crow	A Drug for Longer Lashes? US drugmaker Allergan, the California-based company that makes antiwrinkle treatment Botox, has developed a new cosmetic drug that makes eyelashes grow longer, thicker and darker.
The Motley Fool March 19, 2009 Brian Orelli	Teva: An Equal-Opportunity Bully Making money by picking on the little guy, too.
The Motley Fool March 21, 2005 Rich Duprey	Inamed Buoyant on Medicis Buyout Breast-implant maker Inamed will be acquired in a $2.8 billion deal with skin-care pharmaceutical Medicis. Inamed investors should now decide whether they want to be a part of Medicis or enjoy the profits realized from the offer.
The Motley Fool February 28, 2011 Cindy Johnson	Medicis Pharmaceutical Shares Popped: What You Need to Know Medicis Pharmaceutical Corporation popped 26% in intraday trading today after reporting an inline quarter and announcing a licensing agreement with Teva Pharmaceutical Industries.
The Motley Fool December 31, 2007 Brian Lawler	The Anatomy Of An Approved Drug An independent audit by the FDA provides a useful summary of the characteristics of drugs approved by the agency.
BusinessWeek October 13, 2003 Arlene Weintraub	He Bet on Botox -- And Won David Pyott transformed sleepy Allergan. Where is he taking its blockbuster drug?
CRM February 2003 David Myron	Support Gets a Face-Lift Allergan was able to automate the routing of 80 percent of all inbound, Web-generated emails, based on the business rules the company put in place.
The Motley Fool March 2, 2011 Susmita Chatterjee	How to Capitalize on the Obesity Epidemic Does broader use of Allergan's Lap-Band signify competition for others?
Chemistry World April 29, 2014 Phillip Broadwith	Valeant launches hostile bid for Allergan US drugmaker Valeant has lined up its next takeover target: Botox provider Allergan. Valeant has taken its proposal direct to shareholders, but Allergan has activated a 'poison pill' defense to buy time.
The Motley Fool September 25, 2008 Brian Orelli	Medicis Restates, Investors Panic Medicis says it'll have to restate earnings.
The Motley Fool May 19, 2006 Jim Mueller	Foolish Forecast: Mentor's Uncertain Results Factors outside of the cosmetic surgery products maker's control are leading to short-term uncertainty. Investors, take note.
The Motley Fool April 13, 2009 Brian Orelli	Will These Drugs Get Past the FDA? Hopefully April won't bring showers of tears to these drugmakers: Eli Lilly... AstraZeneca... Bristol-Myers Squibb... Novo Nordisk... Johnson & Johnson...
The Motley Fool November 22, 2006 Brian Lawler	Implant Approval Gives Allergan a Lift The return of silicone breast implants continues. Shares of Allergan, best known for its Botox wrinkle treatment, were up nearly 8% on the news.
The Motley Fool April 14, 2005 Rich Duprey	Mentor the Winner on Implants An FDA panel gives Mentor the right to market breast implants after denying Inamed's application. On the news, Inamed's stock fell by more than 3%, and then nearly 7% in early morning trading.
The Motley Fool January 31, 2007 Brian Lawler	No Earnings Face-Lift Needed For Allergan The ophthalmic and plastic surgery product developer has made many investors rich, and it's not stopping now.
The Motley Fool February 9, 2006 Stephen D. Simpson	Mentor Needs Some Prettying Up Until new products are approved or acquired, the aesthetics and urology company seems stuck in suspended animation. Just standing in place is not going to build much shareholder value.
The Motley Fool October 7, 2009 Jim Mueller	Daily Walk of Shame: Money-Hungry Drugmakers If Allergan wins its suit against the government, consumers will really be in trouble.
The Motley Fool August 31, 2007 Rich Smith	A Healthy Buyback for Medicis? Investors, can Medicis pay its own way? And even if it can, should it?
The Motley Fool November 14, 2007 Brian Lawler	Is the FDA Still Approving New Drugs? Lately the FDA seems more reluctant to approve new drugs than it once was. Let's take a look at the actual numbers from the past eight years.
The Motley Fool July 28, 2011	Medicis Pharmaceutical Earnings Preview Medicis Pharmaceutical will unveil its latest earnings on Tuesday, August 2.
Chemistry World September 6, 2012 Andrew Turley	Valeant buys $2.6bn skincare firm Canadian pharma company Valeant is to buy US firm Medicis in a $2.6 billion deal. Medicis produces prescription dermatology products as well as over the counter products.
The Motley Fool August 17, 2007 Brian Orelli	Fewer Drug Approvals? Buy! Stricter standards at the FDA could create a buying opportunity. Drug approvals are down one third this year, creating a lot of value in pharmaceutical and biotech companies. Just choose your medicines carefully.
Pharmaceutical Executive January 1, 2006 Kenneth I. Kaitin	Opinion: Memo to von Eschenbach FDA's acting commissioner has an opportunity to clarify a lot of misconceptions about the agency's role in regulating drug safety. His first order of business should be to explain exactly what FDA doesn't do.
Pharmaceutical Executive April 1, 2006 Jill Wechsler	Washington Report: A Warning Trend Washington's new answer to drug safety concerns is more warnings and more disclosure of undigested data. But warnings can go too far. Haven't FDA's critics ever heard the story of the boy who cried wolf?
The Motley Fool January 31, 2007 Brian Lawler	FDA Says Hurray for More Drug Safety The FDA outlines its proposal to increase drug safety. Whatever the FDA does, pharmaceutical investors should hope that its renewed interest in drug safety doesn't make the already lengthy process of bringing drugs to market any longer.
Pharmaceutical Executive January 1, 2007 Patrick Clinton	From the Editor: Left Out It's obvious that Democratic legislators plan to change the way drug development and the pharmaceutical industry operate. GAO's report may help them, but they need to know, and soon, there's lots more to learn.
CIO December 14, 2010 Kim S. Nash	How Botox Battles Compliance Wrinkles A BPM overhaul saved the day after legal issues complicated compliance at Botox-maker Allergan.
Chemistry World June 24, 2015 Matthew Gunther	Allergan to buy out Kythera Biopharma for $2.1bn The pharma firm Allergan will acquire Kythera Biopharmaceuticals in a $2.1 billion deal.
The Motley Fool December 20, 2010 Seth Jayson	Should You Get Out of Medicis Pharmaceutical Before Next Quarter? The numbers don't paint a clear picture. For the last fully reported fiscal quarter, Medicis Pharmaceutical's year-over-year revenue grew 16.8%, and its AR grew 138.1%. That's a yellow flag.
The Motley Fool December 29, 2008 Brian Orelli	Thicker Lashes, Fatter Wallets The Food and Drug Administration approves Allergan's Latisse, a treatment for sparse eyelashes.
American Family Physician December 1, 2000 William M. Rados	Online Information for Health Care Professionals The home page of the U.S. Food and Drug Administration has undergone a major revision. The agency's Web site, which includes more than 100,000 documents, is now easier to search and covers the full scope of the FDA's activities...
The Motley Fool October 10, 2005 Stephen D. Simpson	The FDA: Boon, Bane, Whipping Boy Everyone wants the FDA to be faster, better, and cheaper, but that may not be a credible expectation. Investors would do well to keep an eye on the FDA because its policies and pressures ultimately filter down to our medicine cabinets, wallets, and portfolios.
BusinessWeek March 25, 2010 Elizabeth Lopatto	And Now, Gastric Surgery for Kids Allergan wants to market its Lap-Band implants for younger obese patients, but some doctors are balking
Pharmaceutical Executive May 1, 2005 Jill Wechsler	Washington Report: The Pendulum Swings FDA cracks down on safety. Haven't we been here before? Perhaps in the end, the public will have a better understanding of the dangers associated with all pharmaceuticals and how virtually impossible it is to guarantee a risk-free medical treatment.
Chemistry World July 29, 2015 Katrina Megget	Allergan steps away from generics with sale to Teva In something of a surprise move, Allergan has committed to selling its generics business to Israeli generics giant Teva for $40.5 billion, despite having no prior plans to sell.
The Motley Fool September 20, 2007 Brian Lawler	Allergan's Overactive Acquisition Specialty pharma Allergan announced yesterday that it is acquiring privately held Esprit Pharma for $370 million in an all-cash transaction. Investors, take note.
The Motley Fool March 4, 2010 Brian Orelli	A Painless Drug Deal Bristol-Myers licenses pain drug from Allergan.
Health December 2007 Lisa Lombardi	Gynos Removing Wrinkles? Health investigates how the cosmetic-surgery boom is changing the face of doctors' offices everywhere.
Pharmaceutical Executive January 1, 2009 Jill Wechsler	FDA Turnaround Time Will more resources and new leadership fix FDA, or is a major overhaul in order?